In a significant leap forward for tuberculosis (TB) diagnosis, India has developed an indigenous handheld X-ray device aimed at enhancing early detection and treatment efforts. This initiative is part of a broader strategy to improve public health outcomes, according to Indian Council of Medical Research (ICMR) Director General, Dr. Rajiv Bahl.

Speaking at the 19th International Conference of Drug Regulatory Authorities (ICDRA) INDIA-2024, Dr. Bahl emphasized the affordability of the new technology. Developed by Indian Institute of Technology, Kanpur in partnership with ICMR, the handheld X-ray device will cost less than half of the price of imported models. “This will enable TB screening closer to the homes of patients, particularly benefiting vulnerable populations,” Dr. Bahl stated.

Beyond TB, India has also made strides in the fight against Mpox and sickle cell disease. Dr. Bahl announced that three new testing kits for Mpox have been developed, with three companies now manufacturing the kits. He also highlighted a major breakthrough in sickle cell disease diagnosis, with the development of 18 low-cost testing methods. “Each test now costs only 30 rupees, compared to the previous cost of 400 rupees,” he added.

India’s efforts to combat infectious diseases extend further, with the country nearing the development of a dengue vaccine. “We are conducting phase three clinical trials and expect results within the next year. If proven safe and effective, India will soon have its own dengue vaccine,” Dr. Bahl said.

These advancements reflect India’s ongoing commitment to addressing public health challenges and strengthening its healthcare infrastructure.